Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are between 45 and 90 years of age and have active wet age-related macular degeneration (a condition where abnormal blood vessels grow in the back of the eye)
- People whose eye condition is currently showing signs of activity, as seen during a routine eye examination and a special eye scan called an OCT (a painless imaging test of the retina)
- People for whom a treating doctor has already determined that injections into the eye are medically appropriate
Who may not be able to join:
- People who are younger than 45 or older than 90 years of age
- People who have had a stroke, a blood flow problem in the brain, a heart attack, or a coronary stent procedure within the past six months
- People who have uveitis (inflammation inside the eye)
- People whose eye has a clouding problem — such as a significant cataract or cloudy cornea — that prevents clear imaging of the back of the eye
- People who also have other blood vessel-related conditions affecting the retina, such as a blocked vein in the retina or swelling in the central retina caused by diabetes
- People who have an inherited condition that causes the retina to break down over time
- People who have damage or wasting of the optic nerve (the nerve that connects the eye to the brain)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +905380518244
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Best-Corrected Visual Acuity (BCVA) and Central Macular Thickness After MY-1701P Injection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.